In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes by Walker, Mirjam et al.
In vitro effects of nitazoxanide on Echinococcus granulosus
protoscoleces and metacestodes
Mirjam Walker1, Jean Franc¸ois Rossignol2, Paul Torgerson3 and Andrew Hemphill1*
1Institute of Parasitology, Faculties of Veterinary Medicine and Medicine, University of Berne, La¨nggass-Strasse
122, CH-3012 Berne; 3Institute of Parasitology, University of Zu¨rich, Winterthurerstrasse 266a, CH-8057 Zu¨rich,
Switzerland; 2The Romark Institute for Medical Research, Tampa, FL 33607, USA
Received 20 April 2004; returned 19 May 2004; revised 26 May 2004; accepted 29 June 2004
Objectives: Infection of humans and domestic ruminants with the larval stage (metacestode) of Echino-
coccus granulosus results in cystic echinococcosis (CE). The metacestode causes a space-occupying
lesion in visceral organs, most commonly in the liver. Benzimidazole carbamate derivatives, such as
mebendazole and albendazole, are currently used for chemotherapeutic treatment of CE. In human
patients, benzimidazoles have to be applied in high doses for extended periods of time, and adverse
side effects are frequently observed. In order to evaluate alternative treatment options, the in vitro
efficacy of nitazoxanide, a broad-spectrum drug used against intestinal parasites and bacteria, was
investigated.
Methods: Freshly isolated E. granulosus protoscoleces were subjected to nitazoxanide treatment
(1, 5 and 10mg/mL), and the effects on parasite viability were monitored by Trypan Blue staining and
scanning electron microscopy. Protoscolex cultures were maintained further, until metacestode devel-
opment took place. Metacestodes were then subjected to nitazoxanide treatment (10mg/mL), and corre-
sponding effects were visualized by scanning and transmission electron microscopy.
Results: Dose-dependent protoscolex death within a few days of nitazoxanide treatment was observed.
Subsequent in vitro culture of drug-treated protoscoleces confirmed the non-viability of parasites,
while further cultivation of non-treated protoscoleces for a period of at least 3 months resulted in
stage conversion and the formation of small metacestodes 3–4 mm in diameter. Nitazoxanide had a
deleterious effect on these metacestodes, which was comparable to that of albendazole.
Conclusions: Our study indicates a potential for nitazoxanide as an alternative treatment option
against CE.
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Introduction
Cystic echinococcosis (CE) is caused by the metacestode (larval)
stage of Echinococcus granulosus. The disease is found world-
wide, and affects humans as well as domestic livestock including
cattle, sheep, camels, pigs, horses and others.1 In Central Europe
and other industrialized countries, measures such as mandatory
meat inspection have reduced the incidence of the disease,
whereas in countries with lower hygiene standards, E. granulo-
sus infections are commonly observed.1 The definitive host is the
dog, in which adult tapeworms attach to the intestinal epithelium
and undergo sexual reproduction, leading to the development of
eggs. These eggs are shed into the environment with the faeces.
The eggs contain an oncosphere, which upon ingestion by a suit-
able intermediate host and subsequent passage through stomach
and intestine become activated, penetrate the mucosa, enter
blood and lymphatic vessels and are disseminated in the body.2
After an undefined incubation period, E. granulosus meta-
cestodes are formed. These are single, fluid-filled cysts, which
are surrounded by a thick, host-derived layer of connective tissue
(adventitia). The parasite tissue is delineated by the laminated
layer, an acellular, carbohydrate-rich outer surface structure of
considerable thickness, which separates the living parasite tissue
at the inside from the outer host environment. Most human
patients harbour a solitary cyst within a single organ. In 70% of
patients, infection occurs in the liver, the lung being affected in
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20% of patients. Other sites of infection include kidney, spleen,
muscle, skin, abdominal and pelvic cavity, mediastinum, heart,
brain, spinal cord and others.3 Within fertile metacestodes, brood
capsules are formed out of distinct cells originating from the
germinal layer, which themselves contain protoscoleces. Infertile
metacestodes only contain the germinal layer. Often the meta-
cestode contains one or more daughter cysts, which give rise to
the septate appearance in diagnostic imaging.4 The cysts slowly
expand over several years, often without being noticed. Spread
of infection into other sites, such as the peritoneal cavity, has
been described, and this can be caused by cyst rupture and spill-
age of protoscoleces. These have the potential to develop into
metacestodes in the intermediate host, and into adult parasites
when ingested by the final host.2
Treatment of human CE by chemotherapy has been developed
following a series of animal studies, which demonstrated the
efficacy of benzimidazole carbamates against E. granulosus and
Echinococcus multilocularis.5 – 10 Albendazole and mebendazole
are considered to be equally effective. When evaluated up to 12
months after initiation of benzimidazole treatment, 10%–30% of
patients exhibit cyst disappearance, 50%–70% show degene-
ration of cysts and 20%–30% show no morphological changes
in cyst appearance.11,12 Continuous or intermittent treatment with
albendazole is recommended for a period of 6 months. Prazi-
quantel, shown to exhibit protoscolicidal activity, has been
reported to enhance the effect of benzimidazoles, especially
when cyst spillage was considered to pose a problem. In about
75% of patients, metacestodes exhibit clear signs of degenerative
changes.11 However, adverse side effects have been observed
with both benzimidazoles, including abnormalities in liver func-
tion, leucopenia and alopecia, and albendazole has been shown
to be teratogenic in rats and rabbits. It should therefore be
avoided during pregnancy and lactation.3,11,12 As a consequence,
the development of alternative means of treatment of CE is
necessary.
Nitazoxanide [2-acetolyloxy-N-(5-nitro-2-thiazolyl) benza-
mide], originally developed as a veterinary antihelminthic, was
first described in 1984 as a human cestocidal drug.13 To date,
nitazoxanide is known as a broad-spectrum drug against a wide
variety of intestinal parasites and enteric bacteria infecting
animals and humans. Specifically for the treatment of chronic
diarrhoea in immunocompromised patients (e.g. AIDS), nita-
zoxanide has become widely used.14 More recently, we have
reported on the efficacy of nitazoxanide against E. multilocularis
metacestodes in vitro,15 and upon egg infection in the murine
model.16 We have also shown that combined nitazoxanide/
albendazole treatment of mice infected intraperitoneally with
E. multilocularis metacestodes results in a treatment efficacy
that is superior to albendazole alone. This effect was partially
attributed to the fact that combined application of the two drugs
leads to increased albendazole sulphoxide serum levels for
extended periods of time.16 In this study, we report on the in vitro
efficacy of nitazoxanide against E. granulosus protoscoleces and
metacestodes.
Materials and methods
Biochemicals and drugs
If not otherwise stated, all tissue culture media were purchased from
Gibco-BRL (Zu¨rich, Switzerland), and biochemical reagents were
from Sigma (St Louis, MO, USA). Nitazoxanide used in this study
was obtained from Romark Laboratories (Tampa, FL, USA). Alben-
dazole was purchased from GlaxoSmithKline (Germany).
In vitro culture of E. granulosus protoscoleces
and metacestodes
E. granulosus hydatid cysts containing protoscoleces were removed
under aseptic conditions from infected sheep presented for routine
slaughter in abattoirs in Almaty, Kazakhstan. The largely intact
cysts were stored for no longer then 1 week at 48C, during which
time they were transported to Switzerland. In vitro cultivation of
E. granulosus protoscoleces and metacestodes was carried out as
previously described for E. multilocularis metacestodes.17 Briefly,
the hydatid cysts (2–5 cm in diameter) were cut open and vesicle
fluid (containing protoscoleces) was separated from the metacestode
tissue and host adventitia. Protoscoleces were allowed to settle in a
50 mL Falcon tube, were washed twice in Hanks balanced salt
solution and placed into culture medium (RPMI 1640 containing
12 mM HEPES, 2 mM glutamine, 200 U/mL of penicillin,
200mg/mL of streptomycin and 0.50mg/mL of amphotericin B) sup-
plemented with 10% fetal calf serum and phenol red. Cultures were
kept in culture flasks (200 mL) placed in an upright position in an
incubator at 378C, 5% CO2, with medium changes every 4–8 days.
Drug treatment of E. granulosus protoscoleces
Treatment of protoscoleces was initiated within 10 days of in vitro
culture. Three T25 tissue culture flasks containing at least 500 proto-
scoleces in 20 mL culture medium were supplemented with 1, 5 and
10mg/mL nitazoxanide [stock solution in 10 mg/mL in dimethyl
sulphoxide (DMSO)], and one control culture was supplemented
with 20mL DMSO alone. The vitality/viability of protoscoleces was
assessed by observation of motile behaviour and a Trypan Blue
exclusion test, respectively. The corresponding numbers of viable/
non-viable protoscoleces were determined in 10 randomly chosen
fields by phase contrast microscopy using a Leitz DMIL inverted
microscope at 10 magnification. At day 5 following initiation of
drug treatment, the medium±nitazoxanide was removed, parasites
were washed twice in 20 mL Hanks balanced salt solution and cul-
ture was continued in fresh culture medium without nitazoxanide.
Of each culture, a small sample was processed for scanning electron
microscopy (SEM) (see below).
Drug treatment of E. granulosus metacestodes
E. granulosus metacestode formation was achieved by continuing
the culture of protoscoleces for a period of 3–4 months. Parasites
that had undergone stage conversion into small (1–4 mm) hydatid
cysts were collected, split into groups of 40, and resuspended
in 5 mL of culture medium supplemented with nitazoxanide
(10mg/mL) and albendazole (10mg/mL). Two control cultures were
set up in culture medium and medium supplemented with the corre-
sponding amount of DMSO, respectively. Samples for SEM and
transmission electron microscopy (TEM) inspection were taken on
days 0, 4 and 7 following initiation of drug treatment.
SEM and TEM
Protoscoleces and metacestodes were processed as described by
Hemphill & Croft.18 Briefly, parasites were washed once in 100 mM
sodium cacodylate buffer pH 7.2, and placed into the primary fixa-
tive (2.5% glutaraldehyde in 100 mM sodium cacodylate buffer) for
2 h at room temperature. After addition of the fixative, vesicles were
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gently broken up with a pipette. After several washes in cacodylate
buffer, samples were post-fixed in 2% OsO4 in cacodylate buffer.
The specimens were then extensively washed in distilled water.
For SEM analysis, the specimens were dehydrated by sequential
incubations in increasing concentrations of ethanol (50%–70%),
and were finally immersed in hexamethyl-disilazane and air-dried
under a fume hood. They were then sputter-coated with gold, and
inspected on a JEOL 840 scanning electron microscope operating at
25 kV.
For TEM, fixed metacestode vesicles were pre-stained in 1%
uranyl acetate for 30 min at 48C, followed by several washes in
water. They were dehydrated in a graded series of ethanol and sub-
sequently embedded in Epon 812. Polymerization of the resin was
carried out at 658C overnight. Sections 1–2mm thick were cut on a
Reichert and Jung ultramicrotome, loaded onto poly-L-lysine-coated
glass coverslips, and stained with Methylene Blue-Fuchsin. Eighty
nanometre sections were loaded onto 300-mesh copper grids (Plano
GmbH, Wetzlar, Germany), and contrasting with uranyl acetate and
lead citrate was performed, as described previously.18
Results
Effects of nitazoxanide on E. granulosus protoscoleces
Following the isolation of protoscoleces from hydatid cysts, the
Trypan Blue exclusion test revealed that >85% of the parasites
were still viable, and >60% of protoscoleces exhibited distinct
movements. Of those, the majority was invaginated (Figure 1A
and B), but  10%–15% were evaginated; rostellum and suckers
were clearly visible (see Figure 1C), and these regions of the
parasites were the most motile compartments (data not shown).
The decrease in the vitality of the protoscoleces became evi-
dent after 3–4 h following the addition of nitazoxanide, since
movements had ceased, regardless of whether protoscoleces
were invaginated or evaginated. However, Trypan Blue exclu-
sion failed to detect a significant change in viability (data not
shown). Loss of protoscolex viability in nitazoxanide-treated cul-
tures became clearer after 24 h, with a 50% reduction in the
number of viable parasites at 5 and 10mg/mL of nitazoxanide
(see Figure 2). The number of dead protoscoleces increased with
time, and from day 3 onwards, viable parasites could no longer
be seen in cultures treated with 5 and 10mg/mL of nitazoxanide.
Whereas nitazoxanide at 1mg/mL exhibited a less dramatic
Figure 1. Scanning electron microscopy of E. granulosus protoscoleces cultured for 7 days in the presence or absence of nitazoxanide (NTZ; 5mg/mL). A–C
are protoscoleces cultured in medium containing DMSO (1:1000), D–F are protoscoleces cultured in the presence of NTZ. Note the evaginated protoscolex in
C, and the extensive drug-induced damage in D and E. Bars in A = 100mm, B = 30mm, C = 76mm, D = 62mm, E = 90mm, F = 66mm.
Figure 2. Loss of viability of E. granulosus protoscoleces during in vitro
nitazoxanide (NTZ)-treatment. Viability was determined through Trypan
Blue staining. Note the dose-dependent effect of NTZ.
In vitro drug treatment of Echinococcus granulosus
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Figure 3. Scanning electron microscopy of E. granulosus metacestodes. Metacestodes were either kept for 7 days in medium containing DMSO (A, B), or
were treated with 10mg/mL nitazoxanide (NTZ) (C, D). Note the extensive NTZ-induced damage, affecting the germinal layer, with either only residues of
germinal cells present (arrows in C), or only shells of laminated layer (D). GL = germinal layer, LL = laminated layer. Bars in A = 620mm, B = 260mm,
C = 260mm, D = 330mm.
Figure 4. Transmission electron microscopy of E. granulosus metacestode tissue at either timepoint 0 (A, B) or after 7 days of culture in DMSO diluted
1:1000 in medium (C, D). Uc = undifferentiated cell, LL = laminated layer, Te = tegument, GL = geminal layer. Arrows point towards microtriches. Bars in
A = 3.8mm, B = 1.9mm, C = 7.8mm, D = 1.8mm.
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decrease, complete loss of protoscolex viability was observed at
day 7. In contrast, those parasites cultured in the absence of nita-
zoxanide were not significantly altered. SEM demonstrated the
drug-induced morphological and structural damage imposed
upon nitazoxanide-treated protoscoleces (Figure 1D–F).
Resuspension of nitazoxanide-treated protoscoleces in fresh
medium for a period of several weeks without the drug did not
result in any changes, indicating that none of the parasites
had survived the treatment. These results demonstrated the
dose-dependent protoscolicidal effect of nitazoxanide on
E. granulosus. In contrast, a considerable fraction ( 20%) of
protoscoleces, which were not treated with the drug, had under-
gone vesiculation, eventually resulting in metacestode stage con-
version (see below).
In vitro effects of nitazoxanide treatment on E. granulosus
metacestodes
E. granulosus metacestodes were obtained by continuous in vitro
maintenance of the cultures initiated with protoscoleces for a
period of 3–4 months. This resulted in the formation of vesicu-
lated parasites of 1–4 mm in diameter. Inspection of these ves-
icles by SEM revealed that they exhibited features typical of
E. granulosus metacestodes, with a distinct acellular outer lami-
nated layer and an intact germinal layer comprised of a multi-
tude of different, morphologically intact, cell types (Figure 3A
and B). Upon treatment with nitazoxanide and albendazole for
3 days, macroscopic morphological changes became evident in
>50% of metacestodes, most evident through the loss of turgid-
ity. No damage could be seen in the control vesicles. At days
5–7, all vesicles were extensively distorted upon drug treatment,
but control vesicles showed no alteration. Corresponding effects
are illustrated by SEM in Figure 3(C and D). Clearly, at day 7
of treatment with both nitazoxanide and albendazole, in many
areas, only cellular debris of the former germinal layer could be
seen.
These results were confirmed on the ultrastructural level by
TEM. In non-treated control cultures, the external surface of the
metacestodes is comprised of an acellular, amorphous and
heavily glycosylated, laminated layer which surrounds the entire
Figure 5. Transmission electron microscopy of metacestodes treated with nitazoxanide (A–C) or albendazole (D) for a period of 4 days. Note that the tegu-
ment (TE) remains, but effects include increased vacuolization (vac) of the geminal layer (GL), occurrence of lipid droplets (ld), the truncated microtriches
(arrows), and aberrant mitochondria (mit). Bars in A = 1.9mm, B = 0.8mm, C = 0.6mm, D = 2.0mm.
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parasite (Figure 4). Attached to the interior surface of the lami-
nated layer is the tegument, a syncytial parasite tissue with
numerous microtriches protruding into the laminated layer and
thus significantly enhancing the resorbing surface of the parasite.
More towards the interior, the tegument is replaced by the germ-
inal layer, which contains a number of different cell types,
including a number undifferentiated cells with a large nucleus
and nucleolus (Figure 4A and B). Control- and DMSO-treated
cultures exhibited no ultrastructural alterations in parasite tissue
during the entire incubation period of 7 days (Figure 4C and D).
In contrast, both nitazoxanide and albendazole-treated meta-
cestodes had undergone considerable degenerative changes
following 4 days of in vitro treatment, including the extensive
truncation of microtriches. However, the rest of the tegument
was still present, but other structural aberrations became evident.
Treatment with both drugs resulted in the formation of lipid
droplet inclusions, the appearance of rounded mitochondria and
increased vacuolization of the germinal layer (Figure 5). At day
7 of drug treatment, both drugs had induced complete destruc-
tion of the parasite tissue, and only residues of the germinal
layer could be seen still associated with the laminated layer
(Figure 6). In conclusion, in vitro drug treatment with nitazoxa-
nide and albendazole exhibited similar, and clearly parasiticidal,
effects.
Discussion
The aim of this study was to investigate the efficacy of nitazoxa-
nide against the cestode parasite E. granulosus, the causative
agent of CE. In vitro culture of protoscoleces and metacestodes
was employed to demonstrate the parasiticidal effects of nitazox-
anide on both protoscoleces and metacestodes. Recent studies
demonstrating the in vitro and in vivo efficacy of this
drug against E. multilocularis metacestodes15,16 implied that
Figure 6. Transmission electron microscopy of metacestodes treated with nitazoxanide (A, B) and albendazole (C) for 7 days. Note the complete deterio-
ration of the structural integrity of the germinal layer (GL), while the laminated layer (LL) still appears intact. Bars in A = 1.5mm, B = 1.4mm, C = 0.9mm.
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nitazoxanide could also be a promising candidate drug for corre-
sponding treatment against E. granulosus infections. For this
species, it is relevant to investigate these effects on both meta-
cestodes and protoscoleces, since protoscoleces will not only
develop into adult tapeworms in the intestine, but also exhibit
the potential to differentiate into metacestodes when they reach
other organs.2 Thus, they are largely responsible for metastases
formation through spillage of cyst fluid during cyst rupture,
puncture or surgery.3 Prospectively, the introduction of new
drugs could help patients suffering from CE undergo improved
chemotherapy.
Nitazoxanide is a 5-nitrothiazole analogue, with structural
similarities to the benzimidazole antihelminthics such as alben-
dazole and its metabolic derivatives albendazole sulphoxide and
albendazole sulphone, with a 5-nitrothiazole ring substituting the
benzimidazole ring. However, the mode of action of the two
drugs appears to be different. Benzimidazole derivatives bind to
beta-tubulin, and prevent the uptake of glucose by disrupting
cellular microtubular structures. This leads to a reduction in glu-
cose uptake, depletion of glycogen storage, degenerative altera-
tions in the germinal layer and cellular autolysis.19 In bacteria
and in the protozoan parasite Cryptosporidium, nitazoxanide has
been postulated to be reduced to a toxic radical when the
5-nitro-group on the nitroheterocyclic ring reacts with pyruvate:
ferredoxin oxidoreductase.20 Nothing is known about a possible
mode of action of nitazoxanide in helminths. However, the
enzymes of anaerobic electron transport also could be considered
as potential targets.
E. granulosus protoscoleces had been shown earlier to be sus-
ceptible to treatment with the albendazole metabolite albenda-
zole sulphoxide.21 Another drug, which is widely used for
inactivation of protoscoleces, is praziquantel. Praziquantel is a
pyrazinoisoquinoline derivative with a wide antihelminthic spec-
trum including schistosomes, hermaphroditic flukes and cestodes
Whereas it is very effective against adult tapeworms, as well as
against E. granulosus protoscoleces in vitro, in vivo studies on
E. granulosus metacestode infections have been inconclusive.22,23
However, more recently it was suggested that praziquantel exerts
a substantial effect against metacestodes and protoscoleces when
applied in combination with albendazole.24,25
In addition to its efficacy against protoscoleces, nitazoxanide
also exhibits a considerable damaging effect on the metacestode
stage. The high parasiticidal efficacy of nitazoxanide is not sur-
prising, as this compound was shown to exhibit a uniquely wide
spectrum of antiparasitic and antimicrobial activities,14 including
in vitro and in vivo activity against E. multilocularis metaces-
todes.15,16 In vivo pharmacokinetic studies in humans and mice
have shown that nitazoxanide is substantially absorbed following
oral administration, and that it is rapidly hydrolysed to tizoxa-
nide, which is extensively bound to plasma albumin, and later to
tizoxanide glucuronate.16,26,27
Previous studies on E. multilocularis metacestodes treated
with nitazoxanide and albendazole, respectively, had been able
to differentiate between the effects of the two drugs during
in vitro and in vivo treatment.15,16 For instance, the progressive
destruction of E. multilocularis metacestode tissue through
albendazole treatment was characterized primarily by shortening
and distortion of microtriches, followed by other alterations
(vacuolization of the germinal layer, aberrant mitochondria, lipid
droplets, inclusion bodies and loss of cell–cell contacts within a
time frame of 6–10 days).28 In contrast, nitazoxanide treatment
leads first to a marked release of small vesicles from the tegu-
ment into the laminated layer, and the formation of large cyto-
plasmic vacuoles in undifferentiated cells, accompanied by
progressive changes within the germinal layer.15 This indicated
that in E. multilocularis metacestodes the two drugs exhibited
two different modes of action. In contrast, in this study on
E. granulosus metacestodes, we were not able readily to dis-
tinguish between the alterations imposed upon the parasites
through albendazole and nitazoxanide treatment, respectively.
However, a more detailed analysis, involving shorter time
frames, will be necessary to provide respective information.
In conclusion, we here demonstrate the in vitro efficacy and
parasiticidal activity of nitazoxanide against E. granulosus proto-
scoleces and metacestodes. In a next step, we will investigate
the efficacy of nitazoxanide and its derivatives in an animal
model. There, the active compound has to reach the infected
organ and the parasite tissue in a sufficiently high concentration.
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